f-18 rhodamine 6g pet imaging for myocardial blood flow

Conditions: Coronary Artery Disease

Summary: use of novel radio-pharmaceutical rhodamine 6g to determine myocardial blood flow

using rhodamine 6g to determine myocardial blood flow in normal volunteers and patients with coronary heart disease.

Eligibility criteria:
inclusion criteria: * male and female, 21-75 years of age and any race. * capable of giving written informed consent. * "healthy adult volunteer subject" is someone who is volunteering to undergo imaging procedures and based on screening procedures has no known significant health problems. * stable patients with known or suspected coronary artery disease that are scheduled to have or have undergone a clinically indicated conventional rest/stress spect mpi and no intervention between spect and pet. * female subjects must not be pregnant or lactating. exclusion criteria: * has any condition that, in the opinion of the sponsor-investigator or designee could increase risk to the subject, limit the subject's ability to tolerate the research procedures, or interfere with collection of the data. * have abnormal findings on any screening/baseline procedure, e.g. physical examination, laboratory tests, electrocardiogram that suggest the subject might have a condition that could, in the opinion of the sponsor-investigator, affect the subject's response to the radiopharmaceutical or related research procedures. * is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the pet imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history). * has a history of hypersensitivity to fluorine-18 or other radiopharmaceutical or any of its excipients. * have contraindications to cardiovascular pet/ct imaging such as claustrophobia. * have high blood pressure (\>200/110) * have epilepsy * have major kidney or liver problems * have current or past history of major medical illness * currently using recreational drugs * body weight of \> 300 lbs. (weight limit of the pet/ct table) * stable cardiac disease: rest/stress group only: * cardiac patients who suffer an intervening clinical event such as worsening angina pectoris or myocardial infarction or whom undergo a myocardial revascularization procedure or have myocardial ischemia at rest. * sinus node disease (e.g. sa block) or symptomatic bradycardia, second or third degree atrioventricular (av) block. * pre-existing obstructive lung disease (e.g. asthma) that precludes the safe administration of the pharmacological stressor according to the approved label. * uncontrolled and severe hypertension (e.g. systolic blood pressure \>200 mmhg, diastolic blood pressure \>110 mmhg). * baseline hypotension (e.g. systolic blood pressure \< 90 mmhg, diastolic blood pressure \<50 mmhg). * seizures * the use of caffeine, nicotine or over the counter cold medicines within 12 hours prior to stress imaging day with regadenoson. * the theophylline-based medications or dipyridamole within 48 hours prior to each imaging day.